戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 atic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer.
2 ently being given to an extension to include male breast cancer.
3 ress essential questions in the treatment of male breast cancer.
4  little is known about racial disparities in male breast cancer.
5 l implications of this approach to detecting male breast cancer.
6  and/or the presence of one or more cases of male breast cancer.
7  BRCA2-linked families also contain cases of male breast cancer.
8 tional biomarker discovery and validation in male breast cancer.
9 reast cancer, and emerging evidence also for male breast cancer.
10 mline PALB2 PVs and ovarian, pancreatic, and male breast cancers.
11                                Occurrence of male breast cancer, a rare disease, peaks at age 71 year
12 r series, BRCA2 mutations account for 14% of male breast cancer, all but one of which had a family hi
13 mic staging in patients with newly diagnosed male breast cancer and determines detection rates for un
14  (including 3 with ovarian cancer and 1 with male breast cancer) carried none of the three ancient mu
15                                       Of 510 male breast cancer cases (456 white, 34 black), 94% unde
16              A population-based series of 54 male breast cancer cases from Southern California were a
17                                 Most data on male breast cancer comes from small single-institution s
18 conducted a genome-wide association study of male breast cancer comprising 823 cases and 2,795 contro
19 30%-31%) of non-Hispanic White patients with male breast cancer, female breast cancer, or ovarian can
20 : SIR 2.41, 1.67-3.36) and a large excess of male breast cancer (five cases: SIR 15.06, 4.92-35.36).
21              The probability of causation of male breast cancer following radiation exposure exceeds
22                                              Male breast cancer incidence and mortality risk in the J
23 nt (p </= 0.01) dose-related excess risk for male breast cancer incidence and mortality.
24                                   Background Male breast cancer incidence is rising.
25              To enhance our understanding of male breast cancer, international consortia are necessar
26                                              Male breast cancer is a rare disease, accounting for les
27 e paucity of data, the optimal treatment for male breast cancer is not known.
28                       Because of its rarity, male breast cancer is often compared with female breast
29                                              Male breast cancer is rare and has been the focus of lim
30                                              Male breast cancer is rare, but important studies provid
31                                     Although male breast cancer is rare, the reasons for these dispar
32 F7 cells, and an AR mutant (R608K), found in male breast cancer, is associated with the excessive act
33 usion criteria were prostate, testicular, or male breast cancer; known hypogonadism; and HIV.
34                                              Male breast cancer (MBC) is a rare but aggressive malign
35                                              Male breast cancer (MBC) is a rare hormone-driven diseas
36                                              Male breast cancer (MBC) is rare.
37 ated the ATR-Chk1 and ATM-Chk2 signalings in male breast cancer (MBC).
38 ss to care in reducing racial disparities in male breast cancer mortality.
39 mone-related risk factors in the etiology of male breast cancers, no previous studies have examined t
40                           Eight families had male breast cancer; one had a BRCA1 mutation and three h
41 re also associated with an increased risk of male breast cancer, ovarian cancer, prostate cancer and
42                                          Two male breast cancer patients (4% of the total) were found
43                          Only one of the two male breast cancer patients carrying a BRCA2 mutation ha
44                                              Male breast cancer patients have worse survival outcomes
45 eeded to improve information and support for male breast cancer patients.
46 cer by age 50, as well as in three Ashkenazi male breast cancer patients.
47                                   Within the Male Breast Cancer Pooling Project, an international con
48 e joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic dat
49 ncidence patterns showed that the biology of male breast cancer resembled that of late-onset female b
50 at 14q24.1 was significantly associated with male breast cancer risk (P = 3.02 x 10(-13); odds ratio
51  ratios and 95% CIs for associations between male breast cancer risk and 11 individual estrogens and
52 95% CI, 1.24 to 4.50; P = 8.7 x 10(-3)), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P =
53 ortant role for estradiol in the etiology of male breast cancers, similar to female breast cancers.
54 ed all existing prognostic biomarker data in male breast cancer spanning genetics, transcriptomics, p
55  an association of black race with increased male breast cancer-specific mortality.
56 a multidisciplinary international meeting on male breast cancer, sponsored by the National Institutes
57 d ovarian cancer in a single individual, and male breast cancer were all significantly more common in
58           The remaining eight cases (89%) of male breast cancer with a family history of breast/ovari